Zhang M, Qin Y, Wan J, Tian Z, et al. Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by
epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by
epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a
multicentre, randomised, phase III trial. Breast Cancer Res Treat 2026;220:32.
PMID: 43003936
|